CDIO
Cardio Diagnostics Holdings Inc
$1.69
-0.88%
2026-10-23
About Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Key Fundamentals
Forward P/E
-7.80
EPS (TTM)
$-2.90
ROE
-75.4%
Revenue Growth (YoY)
-28.3%
Profit Margin
0.0%
Debt/Equity
4.98
Price/Book
0.78
Beta
2.23
Market Cap
$5.8M
Avg Volume (10D)
33K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$2.34
60D Low
$1.54
Avg Volume
39K
Latest Close
$1.69
Get breakout alerts for CDIO
Sign up for Breakout Scanner to receive daily notifications when CDIO triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Cardio Diagnostics Holdings Inc (CDIO) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CDIO daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CDIO operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.